Today’s Tarot is the VII of Swords, taking power by unconventional means. Science Times reports that the government of India made an end run around American pharmaceutical company, Gilead, for their new drug, Solvaldi.
Gilead can and should make a profit on this radical cure for Hepatitis C, but they priced the drug so high that even the US will struggle to afford a treatment that runs almost $100,000 per person. No one wants to discourage research and investment, but much of that research is done with government money, and there has to be limits on public investment for private gain.
Meanwhile, in parts of the world where Hep C is epidemic and the cost is out of sight, patent law must not stand in the way of saving lives-
“Getting sofosbuvir out of the stronghold of Gilead’s monopoly will be crucial to expanding treatment for people with hepatitis C globally,” says executive director of the Action Campaign of Doctors Without Borders, Dr. Manica Balasegaram.
And with the notion that over three-fourths of the world’s hepatitis c patients would have access to the once off-limit drug only supports India’s decision to cut-off Gilead Science’s tyranny over the Solvadi’s active ingredient, sofosbuvir.
“Gilead’s licensing deal is what we call managed competition,” MSF law partner, Tahir Amin says. “What this case can achieve is open competition, a real free market.”
Like the Dalai Lama said, “understand the rules so you know when to break them.”